Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million FinancingPRNewsWire · 2 days ago
Contrasting PAVmed (NASDAQ:PAVM) and InMode (NASDAQ:INMD)Defense World · Oct 8, 2026
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding PathwaysPRNewsWire · Sep 22, 2026
PAVmed Inc. (PAVM) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 14, 2026
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial ResultsPRNewsWire · Aug 14, 2026
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial ResultsPRNewsWire · Aug 13, 2026PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.47 | -$0.87 | Miss |
| May 15, 2026 | -$0.69 | -$4.42 | Miss |
| Mar 26, 2026 | -$4.50 | -$2.05 | Beat |
| Nov 13, 2025 | -$5.10 | -$8.70 | Miss |
| Aug 14, 2025 | -$3.90 | -$22.20 | Miss |
| May 14, 2025 | -$8.71 | -$2.10 | Beat |